Senhwa Biosciences’ CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

/PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492, “Senhwa”) today announced its official entry into the fast-growing global immuno-oncology market. The…Read More